Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Craig B. Reeder, Donna E. Reece, Vishal Kukreti, Christine Chen, Suzanne Trudel, Kristina Laumann, Joseph Hentz, Nicholas A. Pirooz, Jesus G. Piza, Rodger Tiedemann, Joseph R. Mikhael, Peter L. Bergsagel, Jose F. Leis, Rafael Fonseca, Alexander K. Stewart

Research output: Contribution to journalLetter

143 Scopus citations
Original languageEnglish (US)
Pages (from-to)3416-3417
Number of pages2
JournalBlood
Volume115
Issue number16
DOIs
StatePublished - Apr 22 2010

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C., Trudel, S., Laumann, K., Hentz, J., Pirooz, N. A., Piza, J. G., Tiedemann, R., Mikhael, J. R., Bergsagel, P. L., Leis, J. F., Fonseca, R., & Stewart, A. K. (2010). Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood, 115(16), 3416-3417. https://doi.org/10.1182/blood-2010-02-271676